There are 2137 resources available
1021O - Safety and antitumor activity of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with mesothelioma which is relapsed or refractory to standard therapies
Presenter: Michael Millward
Session: Proffered Paper - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1156O - Surufatinib (S) for patients (Pts) with advanced pancreatic neuroendocrine tumours (SANET-p): A randomized, double-blind, placebo (P)-controlled phase III trial (NCT02589821)
Presenter: Jianming Xu
Session: Proffered Paper - NETs
Resources:
Abstract
Slides
Webcast
1160O - An international open-label study on safety and efficacy of 177Lu-satoreotide tetraxetan in somatostatin receptor positive neuroendocrine tumours (NETs): An interim analysis
Presenter: Guillaume Nicolas
Session: Proffered Paper - NETs
Resources:
Abstract
Slides
Webcast
1157O - A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)
Presenter: Jaume Capdevila
Session: Proffered Paper - NETs
Resources:
Abstract
Slides
Webcast
CN20 - Oral targeted therapy dose adaptation in geriatric cancer patients: A real life French cohort
Presenter: Fanny Leenhardt
Session: EONS13: Phase I clinical trials: What does this mean for our patients?
Resources:
Abstract
Slides
Webcast
1257O - Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)
Presenter: David Hong
Session: Proffered Paper - NSCLC metastatic 1
Resources:
Abstract
Slides
Webcast
1619O - High clinical benefit rates of single agent pembrolizumab in selected rare sarcoma histotypes: First results of the AcSé Pembrolizumab study
Presenter: Jean-Yves Blay
Session: Proffered Paper - Sarcoma
Resources:
Abstract
Slides
Webcast
LBA67 - TRAMUNE, a phase Ib study combining trabectedin and durvalumab, results of the expansion cohort in patients with advanced pretreated soft tissue sarcomas
Presenter: Maud Toulmonde
Session: Proffered Paper - Sarcoma
Resources:
Abstract
Slides
Webcast
LBA68 - Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with metastatic relapsed Ewing sarcoma (ES), on behalf of the French Sarcoma Group (FSG) and UNICANCER
Presenter: Florence Duffaud
Session: Proffered Paper - Sarcoma
Resources:
Abstract
Slides
Webcast
1620O - Phase I study of TK216, a novel anti-ETS agent for Ewing sarcoma
Presenter: Joseph Ludwig
Session: Proffered Paper - Sarcoma
Resources:
Abstract
Slides
Webcast